RecruitingNot ApplicableNCT06633926

Integrative Approaches for Cancer Survivorship (IACS3)

Integrative Approaches for Cancer Survivorship: A Multi-Site Feasibility and Acceptability Study (Aim 2)


Sponsor

University of California, San Francisco

Enrollment

108 participants

Start Date

Mar 31, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial is a two-arm pilot randomized controlled trial for non-metastatic breast cancer survivors to determine the feasibility, acceptability, and fidelity of two integrative health approaches and study design in a multi-site setting. Participants (n=104) will be randomized to either the Ayurveda Intervention (AVI) or Facing Forward Health Education Intervention (FFHEI). Integrative health combines biomedical and complementary approaches together in a coordinated way. AVI, a multi-modal intervention, includes nutritional education, lifestyle practices, yoga, and therapeutic touch, called marma, to help the body and mind feel balanced. FFHEI provides health education using self-directed online content and interactive videos based on the latest science in cancer survivorship. This study does not intend to conduct tests of efficacy and is focused on feasibility outcomes.


Eligibility

Min Age: 18 Years

Inclusion Criteria11

  • Patients
  • Age \>= 18
  • Able to understand study procedures and to comply with them for the entire length of the study.
  • Able to read, write, and understand English.
  • Ability of individual or legal guardian/representative to understand a verbal informed consent document, and the willingness to sign it.
  • Non-metastatic breast cancer patients who are between 1 and 36 months after completion of primary treatment (i.e., surgery, radiotherapy, chemotherapy) and are in a complete remission.
  • Participants should have received chemotherapy as part of their primary treatment.
  • Have an impaired quality of life (report a score of 5 or less on question 30 of the European Organisation for Research and Treatment of Cancer Quality of Life Cancer questionnaire (EORTC-QLQ-C30). "How would you rate your overall quality of life during the past week?"
  • Karnofsky Performance Status Score (KPS) \>=60
  • Ayurveda Practitioners
  • \. Must be engaged as an Ayurvedic Intervention practitioner on the Renew study

Exclusion Criteria11

  • Patients
  • Contraindication to any study-related procedure or assessment.
  • Metastatic disease and receiving chemotherapy or radiotherapy at the time of study enrollment (participants with non-metastatic disease who are receiving anti-Her2 directed treatment alone in the adjuvant setting are eligible).
  • Participants are within 1 month after surgery for cancer, including breast reconstructive surgery but not including implant exchange.
  • Cancer surgery planned during the initial 6-month study period.
  • Been on adjuvant hormone therapy (for breast cancer) less than 2 months at the time of enrollment.
  • Received Ayurvedic treatment during the 3 months preceding enrollment.
  • If a participant reports severe anxiety or depression, has severe depression assessed by Patient Health Questionnaire (PHQ)-9 using a cut-off of 20 or higher, or severe anxiety assessed by the General Anxiety Disorder-7 (GAD-7) using a cut-off 15 or higher.
  • Current suicidal ideation.
  • Ayurveda Practitioners
  • \. None

Interventions

BEHAVIORALNutrition Education

Given nutrition education

BEHAVIORALLifestyle Counseling

Given lifestyle recommendations

OTHERYoga

Participate in yoga

PROCEDUREMarma therapy

Participate in marma therapeutic touch

OTHEREducational Intervention

Attend online HEI sessions

OTHERQuality of Life Questionnaire Administration

Self-reported questionnaires are given to participants to complete


Locations(4)

Zuckerberg San Francisco General

San Francisco, California, United States

University of California, San Francisco

San Francisco, California, United States

Kaiser Permanente Northwest (KPNW)

San Francisco, California, United States

Vanderbilt Ingram Cancer Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06633926


Related Trials